[-] Show simple item record

dc.contributor.authorJackman, Robert
dc.contributor.authorHamilton, Andrew
dc.date.issued2019
dc.description.abstractQ: Does withholding an ACE inhibitor or ARB before surgery improve outcomes? EVIDENCE-BASED ANSWER: A GUARDED YES, because the evidence of benefit is from observational studies and applies to noncardiac surgery. Withholding angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) 24 hours before noncardiac surgery has been associated with a 30-day lower risk for all-cause death, stroke, myocardial injury, and intraoperative hypotension (18% adjusted relative risk reduction). The finding is based on 1 international prospective cohort study and, of note, is an association and a likelihood of benefit. Confirmation would require a large randomized trial (RCT; strength of recommendation [SOR]: B, good-quality international prospective cohort study).eng
dc.description.sponsorshipRobert Jackman, MD Cascades East Family Medicine Residency, Oregon Health and Science University, Portland; Andrew Hamilton, MS, MLS Cascades East Family Medicine Residency, Oregon Health and Science University, Portlandeng
dc.identifier.citationThe Journal of family practice, vol. 68, no 4, May 2019: 238-239.eng
dc.identifier.urihttps://hdl.handle.net/10355/68141
dc.titleDoes withholding an ACE inhibitor or ARB before surgery improve outcomes?eng
dc.title.alternativeDoes withholding an angiotensin-converting enzyme inhabitor or angiotensin receptor blocker before surgery improve outcomes?
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record